SARS-CoV-2–specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Issue 12 (17th November 2021)

• Record Type: Journal Article
• Authors: Bertrand, Dominique; Hamzaoui, Mouad; Drouot, Laurent; Lamulle, Julie; Hanoy, Mélanie; Edet, Stéphane; Laurent, Charlotte; Lebourg, Ludivine; Etienne, Isabelle; Lemoine, Mathilde; Le Roy, Frank; Nezam, Dorian; Mauger, Eleusis; Boyer, Olivier; Guerrot, Dominique; Candon, Sophie
• Is Part Of: Transplantation direct. Volume 7:Issue 12(2021)
• Page Start: e792
• Publication Date: 2021-11-17
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; Transplantation -- Periodicals; 362.19795
• DOI: 10.1097/TXD.0000000000001230
• Languages: English
• ISSNs: 2373-8731

Abstract

Abstract : Background: Kidney transplantation and dialysis are two major risk factors for severe forms of coronavirus disease 2019 (COVID-19). The dynamics of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this population remain largely unknown. Methods: We report here the analysis of anti–SARS-CoV-2 antibody– and T cell–mediated immune responses in 26 kidney transplant recipients (KTRs) and 11 dialyzed patients (DPs) who recovered from COVID-19. Results: After a mean time of 83 ± 26 d post–symptom onset for KTRs and 97 ± 31 d for DPs, 20 KTRs (76.9%) and 10 DPs (90.9%) displayed anti-S1 immunoglobulin G SARS-CoV-2 antibodies ( P = 0.34), at similar titers in both groups. SARS-CoV-2–specific interferon-γ–producing T cells were evidenced in 26 KTRs (100%) and 10 DPs (90.9%). Total numbers of SARS-CoV-2–reactive T cells were high and not statistically different between the 2 groups. No correlation between the severity of the disease and the number of reactive T cells was found in KTRs. In 5 KTRs, also evaluated 10 mo after COVID-19, weak or absent antibody response was observed, whereas specific memory T-cell response was detected in all cases. Conclusion: T-cell response persisted up to 3 mo post–symptom onset, even in KTRs in whom full immunosuppressive regimen was reinstated at recovery, and seems to be present up to 10 mo after infection. Our findings have implications in the understanding of the natural course of the disease in transplant patients and DPs.